94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1485676
This article is part of the Research TopicCommunity Series in Reducing Adverse Effects of Cancer Immunotherapy: Volume IIView all 18 articles
Differences in the count of blood cells in pre-chemotherapy and postchemotherapy of patients with cancer 2022, a retrospective study
Provisionally accepted- Debre Markos University, Debre Marqos, Ethiopia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cancer is a disorder involving uncontrolled growing cells that can invade and spread to other body areas. Drugs used for chemotherapy cause damage to non-cancer cells and lead to a low count of blood cells. There are controversial findings on the difference in the count of blood cell types. Studies are limited on the count of blood cell type before and after chemotherapy. Therefore; this study aimed to address this gap.Method: A retrospective study design was used on 354 patients from September 1, 2022, to October 1, 2022, to compare blood cell type profiles in pre-and post-operative periods. Chisquare and Paired t-test was used to analyze the data.Result: Data were collected from 354 patients. The mean age of the respondent was 41.26 (±16.67). In the first diagnosis, almost all of them reached stage III 167 (47%) and stage IV 159 (45%). The mean hemoglobin level is 12.95g/dl and 12.30g/dl and the prevalence of anemia among cancer patients before chemotherapy and after chemotherapy was 25.14% (95%:20.88, 29.94) and 35.54% (95%: 30.75; 40.73) respectively. The mean value of neutrophil in pre-and post-chemotherapy is 52.72% and 50.82% respectively. The frequency of neutropenia among cancer patients was 22.32% (95% 18.26; 26.96) and 27.97% (95%:23.52; 32.88) before and after chemotherapy respectively and the mean value of lymphocytes is 37.50% and 34.29% in pre and post-chemotherapy respectively. Lymphopenia among the study participants was 16.38% (95%:12.87; 20.62) and 17.51 % (95%13.88; 21.84) in pre and post chemotherapy respectively. Among cancer patients with stomach cancer, rectal cancer, and bone cancer, there is no significant difference in the count of all blood cell types before and after chemotherapy. The mean decrement of platelets is 23. 51×10 3 cells/mm 3 (p=0.001), red blood cell is 0.63×10 6 cells/mm 3 (p=0.08) and white blood cell is 2.49 ×10 6 cells/mm 3 (p=0.012) respectively.After chemotherapy, all hematological parameters were decreased. This means chemotherapy has a significant effect on the number of all hematological parameters and replacement therapy should be considered after chemotherapy.
Keywords: blood cell type, chemotherapy, differences, Patient with cancer, Northern Ethiopia
Received: 30 Aug 2024; Accepted: 25 Mar 2025.
Copyright: © 2025 Kassie, Yimenu, Baye, Shimelash and Asnake. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tadele Derbew Kassie, Debre Markos University, Debre Marqos, Ethiopia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.